• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Longitudinal study of central sensitization and chronic low back pain in a Japanese cohort during the COVID-19 pandemic

tetano

Editor, Senior Moderator
Sci Rep


. 2025 Mar 7;15(1):8012.
doi: 10.1038/s41598-025-93178-z. Longitudinal study of central sensitization and chronic low back pain in a Japanese cohort during the COVID-19 pandemic

Shizumasa Murata[SUP] 1 [/SUP], Hiroshi Hashizume[SUP] 2 3 [/SUP], Kanae Mure[SUP] 4 [/SUP], Hiroyuki Oka[SUP] 5 [/SUP], Shingo Inoue[SUP] 1 [/SUP], Seiji Kanno[SUP] 1 [/SUP], Yuki Matsuyama[SUP] 1 [/SUP], Takeru Ueno[SUP] 1 [/SUP], Akimasa Murata[SUP] 1 [/SUP], Yusuke Kido[SUP] 1 [/SUP], Mayumi Sonekatsu[SUP] 1 [/SUP], Takashi Shimoe[SUP] 1 [/SUP], Hidenobu Tamai[SUP] 1 [/SUP], Ryo Taiji[SUP] 1 [/SUP], Takuhei Kozaki[SUP] 1 [/SUP], Masatoshi Teraguchi[SUP] 1 [/SUP], Yoshio Enyo[SUP] 6 [/SUP], Yukihiro Nakagawa[SUP] 6 [/SUP], Nobuyuki Miyai[SUP] 7 [/SUP], Hiroshi Yamada[SUP] 1 [/SUP]



Affiliations
Abstract

This study utilized a longitudinal survey in Japan to investigate whether higher Central Sensitization Inventory (CSI) scores, serving as a proxy for central sensitization-related symptoms, are associated with an increased risk of developing chronic low back pain (CLBP), focusing on the impact of the coronavirus disease (COVID-19) pandemic on these conditions. Healthy volunteers (n = 227; mean age: 68.5 ± 9.5 years) were surveyed at baseline (July 2019) and at follow-up (October 2020). The participants were categorized into four groups based on their CLBP status: None, De novo, Continued, and Improved. CLBP prevalence increased from 26% at baseline to 32% at follow-up. Higher baseline CSI scores (odds ratio [OR] 1.05, 95% confidence interval [CI] 1.02-1.09; p = 0.005) and older age (OR 1.06, 95% CI 1.02-1.11; p = 0.007) were identified as significant risk factors for developing CLBP. The mean CSI scores exhibited a slight non-significant increase from 16.9 ± 11.4 to 17.1 ± 11.7. Participants who adhered more strictly to the COVID-19 guidelines and engaged in reduced physical activity reported a higher CLBP prevalence. Our findings suggest that early identification and management of central sensitization are crucial for improving clinical outcomes, particularly during periods of external stress, such as the COVID-19 pandemic.

Keywords: COVID-19 pandemic; Central sensitization; Central sensitization inventory (CSI); Chronic low back pain; Longitudinal study; Risk factor.

 
Back
Top Bottom